Barinthus Biotherapeutics (BRNS) AI Stock Analysis

• Market Cap: $27.63M
• Dividend Yield: N/A
• Average Volume (3M): 20.08K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.90
• Revenue Growth: 1773.18%
• EPS Growth: 19.16%
• Country: US
• Employees: 105
• Sector: Healthcare
• Sector Strength: 74
• Industry: Biotechnology
• EPS (TTM): -1.55
• Shares Outstanding: 40,228,455
• 10 Day Avg. Volume: 27,706
• 30 Day Avg. Volume: 20,080
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 2.66
• Price to Cash Flow (P/CF): -0.60
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $4.50
• Price Target Upside: 533.80% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

Barinthus Biotherapeutics' stock score is adversely impacted by significant profitability and cash flow issues, despite notable revenue growth. The technical analysis signals bearish momentum, while negative valuation metrics highlight financial challenges. The restructuring event adds uncertainty, leading to a lower overall score.

Positive Factors

Cash management

The company has extended its cash runway to the start of 2027, based on expected cost savings from the corporate restructuring.

Clinical trial progress

The company is slated to present updated interim data from the Phase 2b trial (HBV003) of VTP-300 in chronic hepatitis B, which could further solidify VTP-300’s position as a potential key component of a functional cure for CHB.

Financial performance

Revenue was $15.0M, which was the company’s share of royalties as a result of prior commercial sales of Vaxzevria by AstraZeneca, beating our projection of zero revenue.

Negative Factors

Clinical trial risk

The probability of approval for VTP-300 has been reduced from 45% to 15%.

Earnings report

For 4Q24, net loss was $20.5M, or ($0.51) per share, more than the estimated loss of $11.5M due to $12.2M of goodwill impairment.

Regulatory risk

Risks include failure of therapeutic candidates in clinical trials and failure to secure regulatory approval.

Barinthus Biotherapeutics Business Overview & Revenue Model

Company Description

Barinthus Biotherapeutics (BRNS) is a cutting-edge biotechnology company focused on developing innovative therapies and solutions in the biotherapeutics sector. The company specializes in creating advanced treatments for complex diseases, leveraging state-of-the-art technology and research to deliver groundbreaking products aimed at improving patient outcomes.

How the Company Makes Money

Barinthus Biotherapeutics generates revenue primarily through the development and commercialization of its proprietary biotherapeutic products. The company engages in strategic partnerships and collaborations with pharmaceutical firms and research institutions to co-develop and license its technologies, providing a significant revenue stream through milestone payments and royalties. Additionally, BRNS may secure funding through government grants and private investments aimed at supporting its research and development efforts. The company also explores opportunities in contract research services, offering its expertise and facilities to other biotech entities for a fee, further diversifying its income sources.

Barinthus Biotherapeutics Financial Statement Overview

Summary

Barinthus Biotherapeutics is experiencing strong revenue growth but continues to face significant challenges with profitability and cash flow. Despite a robust cash position, ongoing net losses and negative cash flows highlight the need for strategic shifts towards sustainable profitability.

Income Statement

Barinthus Biotherapeutics has faced significant challenges with consistent net losses over the years, including a net income loss of $61 million in the most recent year. However, the company showed a remarkable revenue growth from $802,000 to $14.97 million, reflecting a 1766% increase, which is a promising sign. Nevertheless, the negative EBIT and EBITDA margins indicate that profitability remains a significant concern.

Balance Sheet

The company maintains a strong cash position with $110.66 million in cash and equivalents, which is crucial for operations. However, the debt-to-equity ratio has risen to 0.09 from previous years, which is still manageable. The equity ratio has decreased, indicating declining shareholder equity relative to total assets, suggesting that financial stability could be at risk if losses continue.

Cash Flow

Operating cash flow remains negative at -$28.94 million, highlighting ongoing operational challenges. Free cash flow has improved from -$56.34 million to -$29.83 million, but this still signals cash management issues. The lack of positive cash flow presents a risk unless revenue growth translates to improved cash generation.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
14.97M	802.00K	44.70M	268.00K	4.82M
	Gross Profit
14.97M	802.00K	44.70M	268.00K	4.82M
	EBIT
-67.97M	-83.91M	-4.04M	-45.22M	-20.05M
	EBITDA
-55.37M	-71.06M	6.40M	-47.86M	-14.14M
	Net Income Common Stockholders
-61.07M	-73.35M	5.34M	-50.87M	-17.71M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
110.66M	142.09M	194.38M	214.05M	43.27M
	Total Assets
160.33M	214.51M	270.20M	280.71M	50.67M
	Total Debt
12.01M	12.98M	8.77M	7.22M	46.36M
	Net Debt
-98.66M	-129.11M	-185.61M	-206.83M	3.10M
	Total Liabilities
30.19M	27.51M	27.00M	28.15M	87.58M
	Stockholders Equity
130.03M	186.78M	242.90M	252.13M	-37.30M
Cash Flow		Free Cash Flow
-29.83M	-56.34M	-20.57M	-33.73M	-11.32M
	Operating Cash Flow
-28.94M	-50.92M	-14.43M	-32.58M	-11.03M
	Investing Cash Flow
-892.00K	-5.41M	-5.75M	-12.91M	-293.00K
	Financing Cash Flow
2.16M	1.87M	325.00K	222.74M	41.44M

Barinthus Biotherapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.71
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BRNS, the sentiment is Negative. The current price of 0.71 is below the 20-day moving average (MA) of 0.94, below the 50-day MA of 0.98, and below the 200-day MA of 1.17, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 31.25 is Neutral, neither overbought nor oversold. The STOCH value of 29.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BRNS.

Barinthus Biotherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	48 Neutral	$6.36B	1.24	-44.94%	2.70%	18.33%	1.47%
CRSP	46 Neutral	$3.01B	―	-19.20%	―	-89.95%	-123.71%
NTLA	41 Neutral	$677.00M	―	-54.00%	―	59.55%	3.09%
EDIT	39 Underperform	$82.98M	―	-98.10%	―	-58.64%	-40.05%
BLUE	36 Underperform	$46.70M	―	-295.35%	―	184.12%	31.92%
BRNS	35 Underperform	$27.63M	―	-38.49%	―	1773.18%	19.16%
SGMO	35 Underperform	$158.85M	―	-187.83%	―	-67.20%	64.66%

Barinthus Biotherapeutics Corporate Events

Barinthus Biotherapeutics Restructures to Focus on Immunotherapy

Barinthus Biotherapeutics has announced a strategic restructuring plan to prioritize its immune tolerance research and development, resulting in a 65% workforce reduction primarily in the UK. The company aims to extend its cash runway to 2027 by focusing on its U.S. operations and terminating the employment of key executives. This shift underscores Barinthus Bio’s commitment to advancing its immunotherapy platform, with a focus on autoimmune diseases and strategic partnerships for further development of its hepatitis B treatment, VTP-300.